Roche Holding AG’s lung cancer drug scored a big win against a standard therapy in a study this week. Now, the Swiss drugmaker is turning to artificial intelligence to find patients who can benefit.
This content was published on
2 minutes
Bloomberg
When given after surgery to remove lung tumours, Roche’s Alecensa cut the risk of either cancer recurrence or death by 76% compared with standard chemotherapy, according to results from a primary analysis of the trial released Wednesday. The drug could “potentially alter the course of this disease,” Roche Chief Medical Officer Levi Garraway said in a statement.
But finding patients to treat may be difficult: the study examined the effects on people with an error in a gene called ALK that’s found in only about 4% to 5% of lung cancer patients. Most of them are younger and less likely to have smoked than typical lung tumour patients, and often go undiagnosed early on.
To solve the problem, Roche will use an AI collaboration with Israeli tech company Medial EarlySign Ltd. to help doctors determine when to use CT scans. While the technology, called LungFlag, doesn’t currently detect ALK-positive patients, the company said on Saturday that it’s actively exploring how to expand it so they can benefit.
That will help find tumours before they spread and while needed surgery is still possible, said Charlie Fuchs, Roche’s head of oncology and haematology drug development.
“Sometimes when you really use deep data algorithms, you may find things that identify people who are non-smokers and yet at risk,” Fuchs said in an interview. “We hope more patients can be found early and benefit from this.”
Roche has said it will file the Alecensa study results with regulators for approval. The full results were presented Saturday at the European Society for Medical Oncology meeting in Madrid. Alecensa is already approved in the US, Europe, Japan and China for patients with ALK-positive metastatic lung cancer.
Analysts anticipate that Alecensa will generate CHF1.56 billion ($1.75 billion) in sales this year. That it would be a blockbuster medicine even though it treats such a small portion of lung cancer patients shows that effective drugs don’t have to serve a big patient population to be scientific and financial successes, Fuchs said.
Popular Stories
More
Swiss Politics
In Switzerland, New Year brings ‘burka ban’ and pension hikes
Have you heard something about Swiss diplomacy that you’d like us to fact check?
Not all information circulating about Switzerland’s foreign relations is accurate or well understood. Tell us what you'd like us to fact check or clarify.
‘One million stars’ against poverty light up Swiss parliament square
This content was published on
Swiss charity Caritas lit thousands of candles on parliament square in Bern on Saturday evening to mark the "A Million Stars" solidarity campaign, a reminder that many people in Switzerland still live in poverty.
This content was published on
The Eurovision Song Contest shows are in high demand, with the result that profiteers are hoping to make a quick franc by buying up lots of tickets.
Former Swiss finance minister slams report on Credit Suisse collapse
This content was published on
Former Swiss Finance Minister Ueli Maurer has criticised a parliamentary report on UBS's takeover of Credit Suisse, rejecting accusations that he hid the seriousness of the situation from the government.
This content was published on
Researchers in Zurich have developed an electricity-free dehumidifier. It is a building element that allows walls and ceilings to absorb moisture from the air and store it temporarily.
Swiss man found dead in Iranian prison had allegedly collected soil samples
This content was published on
The Swiss man who died in an Iranian prison is said to have secretly taken soil samples beforehand, according to Iranian media.
This content was published on
Hackers have attacked the Swiss federal administration. Among other things, telephones, email and various federal websites and specialist applications were affected.
More and more Swiss celebrities and institutions leaving X
This content was published on
The short messaging service X has also lost its reputation in Switzerland. More and more personalities and institutions are turning their backs on tech billionaire Elon Musk's platform.
Driver going wrong way causes accident in Gotthard tunnel
This content was published on
A 76-year-old driver going in the wrong direction caused a head-on collision on the A2 motorway in canton Uri on Friday. Five people were injured.
Opponents of Crans-Montana ski work appeal to Federal Court
This content was published on
Opponents of the new finishing area stadium for the national piste in Crans-Montana, site of the 2027 Alpine World Ski Championships, have appealed to the Swiss Federal Court.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.